Tremfya Phase III Maintenance Study Results Presented by J&J for Ulcerative Colitis Treatment

J&J, Johnson & Johnson, Tremfya, guselkumab, Phase III trial, maintenance study, ulcerative colitis, inflammatory bowel disease, treatment, efficacy, safety, remission.

AstraZeneca’s COVID-19 Antibody Treatment Shows Promising Results in Immunocompromised Individuals

AstraZeneca, COVID-19, antibody treatment, immunocompromised individuals, enhanced protection, clinical trials, monoclonal antibodies, virus neutralization, immune response.

Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition

Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.

AstraZeneca Strengthens Partnership with Cellectis in Cell and Gene Therapy Advancement

AstraZeneca, Cellectis, cell therapy, gene therapy, partnership, stake, discovery, pact, biotechnology, healthcare, investment, innovation, medical research, therapeutic development.